Castle Biosciences, Inc. (CSTL)
Market Cap | 581.41M |
Revenue (ttm) | 250.73M |
Net Income (ttm) | -30.80M |
Shares Out | 27.61M |
EPS (ttm) | -1.14 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 492,180 |
Open | 19.71 |
Previous Close | 19.31 |
Day's Range | 19.08 - 21.08 |
52-Week Range | 12.07 - 25.91 |
Beta | 0.93 |
Analysts | Strong Buy |
Price Target | 31.00 (+47.2%) |
Earnings Date | Aug 5, 2024 |
About CSTL
Castle Biosciences, Inc., a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett’s esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with d... [Read more]
Financial Performance
In 2023, CSTL's revenue was $219.79 million, an increase of 60.38% compared to the previous year's $137.04 million. Losses were -$57.47 million, -14.41% less than in 2022.
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for CSTL stock is "Strong Buy." The 12-month stock price forecast is $31.0, which is an increase of 47.20% from the latest price.
News
![](https://cdn.snapi.dev/images/v1/j/q/press13-2536171.jpg)
Castle Biosciences and Skin Cancer Survivor Teddi Mellencamp Arroyave Launch Campaign to Increase Awareness of Melanoma
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle Biosciences and skin cancer survivor Teddi Mellencamp Arroyave launch campaign aimed at empowering patients impacted by melanoma.
![](https://cdn.snapi.dev/images/v1/c/o/conf19-2524560.jpg)
Castle Biosciences to Release Second Quarter 2024 Financial Results and Host Conference Call on Monday, Aug. 5, 2024
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle will release its financial results for the second quarter and six months ended June 30, 2024, after the close of market on Mond...
![](https://cdn.snapi.dev/images/v1/v/y/press11-2519242.jpg)
Castle Biosciences Honored with Top Workplaces Awards
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle honored as an Arizona Top Workplace, a national Healthcare Industry Top Workplace and receives five Top Workplaces Culture Exce...
![](https://cdn.snapi.dev/images/v1/h/u/gen54-2478482-2512758.jpg)
Top 5 Health Care Stocks That May Explode In July
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
![](https://cdn.snapi.dev/images/v1/7/z/press19-2492408.jpg)
Recent AGA Clinical Practice Guideline Acknowledges That Individuals Who May Be at Increased Risk of Progression to Esophageal Cancer Might Be Identified Using Tissue-Based Biomarkers, Particularly Castle Biosciences' TissueCypher® Test
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #AGA--The latest AGA clinical practice guideline acknowledges the role that TissueCypher can play identifying high-risk Barrett's esophagus patients.
![](https://cdn.snapi.dev/images/v1/e/w/press8-2487599.jpg)
Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle Biosciences reports inducement grants under Nasdaq Listing Rule 5635(c)(4).
![](https://cdn.snapi.dev/images/v1/u/r/press15-2480606.jpg)
Castle Biosciences' Founder, President and CEO Derek Maetzold Named an EY Entrepreneur Of The Year® 2024 Gulf South Award Winner
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle's founder, president & CEO, Derek Maetzold, has been named an EY 2024 Entrepreneur Of The Year® for the Gulf South region.
![](https://cdn.snapi.dev/images/v1/t/l/conf6-2455050.jpg)
Castle Biosciences to Present New Data at 2024 ASCO® Annual Meeting Highlighting Use of DecisionDx®-Melanoma to Identify Early-Stage Melanoma Patients at High Risk of Metastasis to the Central Nervous System to Prompt Use of Imaging Surveillance
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #ASCO--Castle will present new data related to its DecisionDx-Melanoma and DecisionDx-UM tests at the 2024 ASCO Annual Meeting, May 31-June 4, 2024.
![](https://cdn.snapi.dev/images/v1/p/0/press13-2452636.jpg)
New Publication Shows DecisionDx®-SCC Identifies High-Risk Squamous Cell Carcinoma Patients Who Are Likely to Benefit from Adjuvant Radiation Therapy and Those Who Can Consider Deferring Treatment Based on Biological Risk of Metastasis
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle announced the publication of a study demonstrating the impact of the DecisionDx-SCC test in guiding adjuvant radiation therapy decision-maki...
![](https://cdn.snapi.dev/images/v1/h/n/conf18-2431680.jpg)
Castle Biosciences to Present at the Leerink Partners Healthcare Crossroads Conference
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle executive management is scheduled to present a company overview at the Leerink Partners Healthcare Crossroads Conference May 29...
![](https://cdn.snapi.dev/images/v1/z/u/press5-2428963.jpg)
Castle Biosciences Expands Evidence Supporting the Performance of its TissueCypher® Barrett's Esophagus Test in Predicting Future Development of Esophageal Cancer Through Multiple Data Presentations at DDW 2024
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #Barrettsesophagus--Castle will share three abstracts related to its TissueCypher® test at DDW 2024.
![](https://cdn.snapi.dev/images/v1/g/p/press20-2423701.jpg)
Castle Biosciences' IDgenetix® Test Receives 2024 MedTech Breakthrough Award for “Best Overall Mental Health Solution”
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle awarded the “Best Overall Mental Health Solution” in 8th annual MedTech Breakthrough Awards program for IDgenetix® pharmacogeno...
![](https://cdn.snapi.dev/images/v1/v/d/press10-2421673.jpg)
Largest Prospective Study to Date Further Supports Performance of DecisionDx®-UM for Metastatic Risk Stratification in Uveal Melanoma and Utility of PRAME Biomarker for Refining Risk When Considered with DecisionDx-UM Class Result
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #COOG--Castle announced data supporting the utility of the PRAME biomarker as a risk refinement tool when considered in the context of a DecisionDx-UM res...
![](https://cdn.snapi.dev/images/v1/o/2/press13-2408750.jpg)
DecisionDx®-SCC Significantly Improves Prediction Accuracy of Metastatic Events after Mohs Surgery in New Study of Patients with High-Risk Cutaneous Squamous Cell Carcinoma Tumors of the Head and Neck
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #ACMS--Castle Biosciences will share new data supporting the utility of its DecisionDx®-SCC test at the ACMS Annual Meeting in Phoenix.
![](https://cdn.snapi.dev/images/v1/w/b/press16-2407600.jpg)
Castle Biosciences Reports First Quarter 2024 Results
FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced its financial results for the...
![](https://cdn.snapi.dev/images/v1/1/w/press2-2401322.jpg)
Castle Biosciences Kicks off Skin Cancer Awareness Month with a Ribbon Cutting to Celebrate the City of Friendswood's Designation as a Sun Safe Leadership Model City by IMPACT Melanoma
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle Biosciences announced its support of key skin cancer advocacy events and initiatives throughout May in honor of Skin Cancer Awareness Month.
![](https://cdn.snapi.dev/images/v1/u/x/conf19-2366796.jpg)
Castle Biosciences to Release First Quarter 2024 Financial Results and Host Conference Call on Thursday, May 2, 2024
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle will release its financial results for the first quarter ended March 31, 2024, after the close of market on Thursday, May 2, 20...
![](https://cdn.snapi.dev/images/v1/9/y/press13-2366318.jpg)
Castle Biosciences Celebrates Esophageal Cancer Awareness Month through Advocacy and Educational Collaborations
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle recognizes the importance of Esophageal Cancer Awareness Month and is providing its support of key programs and initiatives thr...
![](https://cdn.snapi.dev/images/v1/n/j/press16-2364804.jpg)
Castle Biosciences' Chief Financial Officer Frank Stokes Recognized as a Top CFO of Houston for Second Consecutive Year
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--For the second year in a row, Castle's chief financial officer, Frank Stokes, has been selected as a Top 25 CFO of Houston by TOP CFOs...
![](https://cdn.snapi.dev/images/v1/w/c/press20-2357573.jpg)
Presentations at EADO Highlight Potential Impact of Castle Biosciences' DecisionDx®-Melanoma and DecisionDx®-SCC Tests on the Management of Patients with Skin Cancer
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle will share new data on its DecisionDx-Melanoma and DecisionDx-SCC tests at the 20th European Association of Dermato-Oncology (EADO) Congress...
![](https://cdn.snapi.dev/images/v1/k/n/conf5-2351606.jpg)
Castle Biosciences to Present at the 23rd Annual Needham Virtual Healthcare Conference
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle's executive management will present a company overview at the 23rd Annual Needham Virtual Healthcare Conference Tuesday, 4/9/24...
![](https://cdn.snapi.dev/images/v1/2/w/press9-2345016.jpg)
Castle Biosciences Announces Updates to its Board of Directors
FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle today announced that Rodney Cotton has been appointed to its board of directors, effective immediately.
![](https://cdn.snapi.dev/images/v1/s/1/press16-2339367.jpg)
Castle Biosciences Earns a Top Workplaces USA Award for the Third Consecutive Year
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle announced it has received a Top Workplaces USA award for the third consecutive year.
![](https://cdn.snapi.dev/images/v1/i/9/press13-2338209.jpg)
Long-term Outcomes Data Shared at SSO 2024 Show That Patients with a Low-Risk DecisionDx®-Melanoma Test Result Were Recurrence Free at Three Years, Including Those Who Utilized the Test to Help Guide the Decision to Avoid an SLNB
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle announced new data highlighting the performance of its DecisionDx-Melanoma test in predicting risk of SLN positivity in patients with melano...
![](https://cdn.snapi.dev/images/v1/n/c/press6-2330487.jpg)
Leading Squamous Cell Carcinoma Practitioners Publish Consensus Guidelines Integrating DecisionDx®-SCC into a Clinical Workflow to Improve Decision-Making Regarding the Use of Adjuvant Radiation Therapy
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #40GEP--Expert consensus article in JCAD recommends framework including DecisionDx-SCC test for adjuvant radiation therapy decision-making in SCC patients...